Biliary AtresiaK-LNMCNCT02292862
Maternal Microchimerism in Lymph Nodes of Infants With Biliary Atresia at Time of Kasai's Operation
An observational study of Biliary Atresia, run by Medizinische Hochschule Brandenburg Theodor Fontane at 1 site in Germany.
Trial summary
Maternal microchimerism has been discussed as an etiological mechanism in infantile (perinatal) biliary atresia (BA). In Kasai's operation (resection of the liver hilum plaque followed by hepato-portoenterostomy) surgeons frequently encounter swollen portal and mesenteric lymph nodes. Read more about this study
- Who is it for?
- Ages 4 weeks to 5 months
- Conditions the study is for
- Biliary Atresia
- What is being tested?
- Lymph node and blood sampling
- Type of treatment
- Surgery or procedure
- How many people
- 7 participants
- Where
- 1 siteGermany
- Study dates
- Nov 2012to Nov 2014
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 4 weeks to 5 months
- All sexes
- No healthy volunteers
- Child
Study population: Children with newly and preoperatively diagnosed infantile Biliary Atresia of the non-syndromatic form
Who may be able to join
- Non-Syndromatic Form of Biliary Atresia
Who cannot join
- Syndromatic Form of Biliary Atresia
- Other Congenital Liver Disease (Like Alagilles' Syndrome)
- No liver fibrosis/cirrhosis in Histology of LIver Specimen from Routine Histology
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Search for Maternal Microchimerism in Swollen Portal Lymph Nodes of Infants With Biliary Atresia.
Maternal microchimerism has been discussed as an etiological mechanism in infantile (perinatal) biliary atresia (BA). In Kasai's operation (resection of the liver hilum plaque followed by hepato-portoenterostomy) surgeons frequently encounter swollen portal and mesenteric lymph nodes.
Lymph nodes were sampled during Kasai' s operation and examined for maternal DNA.
Read the detailed description
Upon operation of infants with non-syndromatic biliary atresia (BA, commonest form), surgeons almost invariably note the prominent finding of multiple swollen lymph nodes of up to 2 cm in size in the porta hepatis and the small bowel mesentery where they may constitute grape like complexes. Same-age infants laparotomized for other pathology commonly do not present such nodes.
Biliary atresia is a disease of the newborn which is fatal when left untreated. Histologically it corresponds to a degeneration of intra- und extra hepatic bile ducts within a in part specific inflammatory infiltrate and progressive cirrhosis.
The etiology of this rare but constant disease (1:8-1:15.000) is unknown. Currently in BA etiology research two main avenues are pursued:
- Virally induced perinatal (auto)immune processes are suspected. An experimental form of BA can be provoked by infecting murine mothers with dsRNA-viruses e.g. Rhesus-rotaviruses or Reo-viruses while in mice, vaccination of mothers has prevented experimental BA . The importance of the γ/δ-T-cell and IL17/IL 23 pathway , for BA is currently probed. However, in groups of syngenic animals treated by the same batch of viruses BA tends to be inconstant and it is limited to extrahepatic bile ducts such as about the validity of the animal model is an issue.
- The other direction of research does not primarily rely on experiments involving newborn animals: There are indications that during pregnancy the placental barrier may become permeable for maternal lymphocytes (e.g. by a faulty silencing of T-cell attracting chemokines in decidual stroma cells) and already in 2008 maternal lymphocytes have been demonstrated in livers of BA infants . Subsequently the phenomenon of materno-fetal microchimerism has come into focus of BA ethiology research: in the context of mixed materno-fetal immune reactions cells of maternal origin could misdirect the immature immune system of the infant into auto-immunity or act directly as effectors in a graft vs. host like fashion.
The importance of mesenteric and portal lymph nodes for maturation of the immune system during pregnancy has been reported recently . Moreover it has been demonstrated that flow the between liver and portal lymph nodes is bidirectional . In In mice the frequence of CD4+ and FoxP3+ regulatory T-cells was found to be linked to the mothers immune status. We thus hypothesized that the prominently swollen lymph nodes of BA infants which surgeons constantly encounter during Kasai's operation may hold a key to the better understanding of pathophysiological important lymphocyte trafficking mechanisms.
In the standard operation, the Kasai-operation which in a race with increasing liver cirrhosis makes sense up to an age of 4 months, the degraded rests of the major bile ducts in the liver hilus (the so called "hilar plate") are resected, A Roux y-loop is sutured onto the resection site. It shall drain any contingent bile flow from remaining bile ducts. The long term success rate of this tentative of surgical cure which is of moderate technical complexity and invasiveness is estimated to ca. 15-20%. In the remaining a partly sucess may postpone the necessity of liver transplantation. We examined in seven consecutive patients with histologically proven biliary atresia whether in periportal lymph nodes there was evidence for maternal gentic material.
Methods :
7 consecutive patients with the preoperative diagnosis of BA were included in the study. Other causes of icterus prolongatus (α1 anti-trypsin deficiency, Alagilles syndrom, PFIC etc.) had been excluded amongst the methods technical successful ERCP (5/7 patients) which showed absence of intrahepatic bile ducts.
After obtaining the parent's informed consent 2 ml EDTA whole blood were collected from mother and infant. During Kasai's operation one portal and one mesenterial lymphnode were sampled (Hannover Medical School ethical committee vote No.1650/11.12.2012. After bipolar dissection the mesenteric gaps were closed with 4-0 Vicryl sutures.
Lymph nodes were disrupted mechanically and DNA was extracted enzymatically (QIAmp Kit, Qiagen, Hilden/Germany) as described previously and normalized to 30 ug/ml.
Short tandem repeat analysis was realized with multiplex PCR for markers LIPOL, VWA, TH01, D19S253, CSF, PLA2A. FGA, D21S11, D18S51 as described. Briefly, fragment length analysis was performed an Abi Prism 310 System with GeneScan 3.11. software for comparison of mother's and infant's blood with lymph node DNA.
Genetic single nucleotide polymorphisms (SNPs) were traced by quantitative real time PCR chimerism analyses. Reactions were executed on an iCycler iQ5 real-time PCR platform (Bio-Rad) using the ABsolute QPCR Rox Mix (Thermo scientific). Custom designed primers and probes were provided by Sigma-Aldrich. Control reactions and normalization of sample DNA were performed by amplifying the albumin gene.
- Conditions
- Biliary Atresia
- Being tested
- Lymph node and blood sampling
- Medical subject headings
- Biliary Atresia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Lymph node and blood samplingProcedure or surgery
By bipolar dissection 1 portal and 1 mesenteric lymph node are removed from the infant.
Blood (1ml) is taken from mother and infant.
| Study group | Role | What they receive |
|---|---|---|
| MG Main Group | lymph node and blood sampling Receives: Procedure: Lymph node and blood sampling |
What is being measured
The primary outcome is the main question the study is designed to answer.
Maternal DNA in offspring
The presence of maternal DNA in the childs blood and lymph nodes is the endpoint
Measured: 3 months
Secondary outcomes (2)
Serum Bilirubin
Measured: perioperatively
Composition of lymphocyte population in mesenteric lymph nodes
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Nov 2014 (estimated)
- Study startNov 2012
- Primary completionNov 2013
- Study completionNov 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Biliary AtresiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 7 participants (actual)
Sponsor and investigators
- Lead sponsor
- Medizinische Hochschule Brandenburg Theodor Fontane
- Sponsor type
- University, hospital or other
- Collaborators
- Johann Wolfgang Goethe University Hospital
- Responsible party
- Principal investigator, Carsten Engelmann, Medizinische Hochschule Brandenburg Theodor Fontane
- Investigators
- Carsten R Engelmann, MD, OhD, Principal investigator, Klinikum Brandenburg
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02292862
- Sponsor's protocol ID
- Trial 1650 12
- Acronym
- K-LNMC
- Status last verified
- Nov 2014
- First submitted
- 13 Nov 2014
- Last updated
- 17 Nov 2014
- Results posted
- No
- Data monitoring committee
- No
Publications
Leveque L, Hodgson S, Peyton S, Koyama M, MacDonald KP, Khosrotehrani K. Selective organ specific inflammation in offspring harbouring microchimerism from strongly alloreactive mothers. J Autoimmun. 2014 May;50:51-8. doi: 10.1016/j.jaut.2013.10.005. Epub 2013 Nov 20.
PubMed 24268809Willasch A, Schneider G, Reincke BS, Shayegi N, Kreyenberg H, Kuci S, Weber G, Van Der Reijden B, Niethammer D, Klingebiel T, Bader P. Sequence polymorphism systems for quantitative real-time polymerase chain reaction to characterize hematopoietic chimerism-high informativity and sensitivity as well as excellent reproducibility and precision of measurement. Lab Hematol. 2007;13(3):73-84.
PubMed 17984038Engelmann C, Maelzer M, Kreyenberg H. Absence of Maternal Microchimerism in Regional Lymph Nodes of Children With Biliary Atresia. J Pediatr Gastroenterol Nutr. 2016 Jun;62(6):804-7. doi: 10.1097/MPG.0000000000001093.
PubMed 26756872
Study at a glance
From the registry record, last updated by the sponsor on 17 Nov 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Search for Maternal Microchimerism in Swollen Portal Lymph Nodes of Infants With Biliary Atresia.
- ClinicalTrials.gov ID
- NCT02292862
- Acronym / sponsor ID
- K-LNMC / Trial 1650 12
- Conditions
- Biliary Atresia
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 7 participants (actual)
- Lead sponsor
- Medizinische Hochschule Brandenburg Theodor FontaneUniversity, hospital or other
- Collaborators
- Johann Wolfgang Goethe University Hospital
- Study start
- Nov 2012
- Primary completion
- Nov 2013 (actual)
- Study completion
- Nov 2014 (actual)
- First posted
- 17 Nov 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Maternal microchimerism has been discussed as an etiological mechanism in infantile (perinatal) biliary atresia (BA). In Kasai's operation (resection of the liver hilum plaque followed by hepato-portoenterostomy) surgeons frequently encounter swollen portal and mesenteric lymph nodes.
Lymph nodes were sampled during Kasai' s operation and examined for maternal DNA.
Detailed description
Upon operation of infants with non-syndromatic biliary atresia (BA, commonest form), surgeons almost invariably note the prominent finding of multiple swollen lymph nodes of up to 2 cm in size in the porta hepatis and the small bowel mesentery where they may constitute grape like complexes. Same-age infants laparotomized for other pathology commonly do not present such nodes.
Biliary atresia is a disease of the newborn which is fatal when left untreated. Histologically it corresponds to a degeneration of intra- und extra hepatic bile ducts within a in part specific inflammatory infiltrate and progressive cirrhosis.
The etiology of this rare but constant disease (1:8-1:15.000) is unknown. Currently in BA etiology research two main avenues are pursued:
- Virally induced perinatal (auto)immune processes are suspected. An experimental form of BA can be provoked by infecting murine mothers with dsRNA-viruses e.g. Rhesus-rotaviruses or Reo-viruses while in mice, vaccination of mothers has prevented experimental BA . The importance of the γ/δ-T-cell and IL17/IL 23 pathway , for BA is currently probed. However, in groups of syngenic animals treated by the same batch of viruses BA tends to be inconstant and it is limited to extrahepatic bile ducts such as about the validity of the animal model is an issue.
- The other direction of research does not primarily rely on experiments involving newborn animals: There are indications that during pregnancy the placental barrier may become permeable for maternal lymphocytes (e.g. by a faulty silencing of T-cell attracting chemokines in decidual stroma cells) and already in 2008 maternal lymphocytes have been demonstrated in livers of BA infants . Subsequently the phenomenon of materno-fetal microchimerism has come into focus of BA ethiology research: in the context of mixed materno-fetal immune reactions cells of maternal origin could misdirect the immature immune system of the infant into auto-immunity or act directly as effectors in a graft vs. host like fashion.
The importance of mesenteric and portal lymph nodes for maturation of the immune system during pregnancy has been reported recently . Moreover it has been demonstrated that flow the between liver and portal lymph nodes is bidirectional . In In mice the frequence of CD4+ and FoxP3+ regulatory T-cells was found to be linked to the mothers immune status. We thus hypothesized that the prominently swollen lymph nodes of BA infants which surgeons constantly encounter during Kasai's operation may hold a key to the better understanding of pathophysiological important lymphocyte trafficking mechanisms.
In the standard operation, the Kasai-operation which in a race with increasing liver cirrhosis makes sense up to an age of 4 months, the degraded rests of the major bile ducts in the liver hilus (the so called "hilar plate") are resected, A Roux y-loop is sutured onto the resection site. It shall drain any contingent bile flow from remaining bile ducts. The long term success rate of this tentative of surgical cure which is of moderate technical complexity and invasiveness is estimated to ca. 15-20%. In the remaining a partly sucess may postpone the necessity of liver transplantation. We examined in seven consecutive patients with histologically proven biliary atresia whether in periportal lymph nodes there was evidence for maternal gentic material.
Methods :
7 consecutive patients with the preoperative diagnosis of BA were included in the study. Other causes of icterus prolongatus (α1 anti-trypsin deficiency, Alagilles syndrom, PFIC etc.) had been excluded amongst the methods technical successful ERCP (5/7 patients) which showed absence of intrahepatic bile ducts.
After obtaining the parent's informed consent 2 ml EDTA whole blood were collected from mother and infant. During Kasai's operation one portal and one mesenterial lymphnode were sampled (Hannover Medical School ethical committee vote No.1650/11.12.2012. After bipolar dissection the mesenteric gaps were closed with 4-0 Vicryl sutures.
Lymph nodes were disrupted mechanically and DNA was extracted enzymatically (QIAmp Kit, Qiagen, Hilden/Germany) as described previously and normalized to 30 ug/ml.
Short tandem repeat analysis was realized with multiplex PCR for markers LIPOL, VWA, TH01, D19S253, CSF, PLA2A. FGA, D21S11, D18S51 as described. Briefly, fragment length analysis was performed an Abi Prism 310 System with GeneScan 3.11. software for comparison of mother's and infant's blood with lymph node DNA.
Genetic single nucleotide polymorphisms (SNPs) were traced by quantitative real time PCR chimerism analyses. Reactions were executed on an iCycler iQ5 real-time PCR platform (Bio-Rad) using the ABsolute QPCR Rox Mix (Thermo scientific). Custom designed primers and probes were provided by Sigma-Aldrich. Control reactions and normalization of sample DNA were performed by amplifying the albumin gene.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| MG Main Group | – | Procedure: Lymph node and blood samplinglymph node and blood sampling |
Who may qualify
- Ages
- 4 weeks to 5 months
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
- Study population
- Children with newly and preoperatively diagnosed infantile Biliary Atresia of the non-syndromatic form
Key inclusion criteria (1 listed)
- Non-Syndromatic Form of Biliary Atresia
Key exclusion criteria (3 listed)
- Syndromatic Form of Biliary Atresia
- Other Congenital Liver Disease (Like Alagilles' Syndrome)
- No liver fibrosis/cirrhosis in Histology of LIver Specimen from Routine Histology
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Lymph node and blood samplingBy bipolar dissection 1 portal and 1 mesenteric lymph node are removed from the infant. Blood (1ml) is taken from mother and infant. | Procedure or surgery | MG Main Group |
Primary outcome
Maternal DNA in offspring
Time frame: 3 months
The presence of maternal DNA in the childs blood and lymph nodes is the endpoint
2 secondary outcomes
Serum Bilirubin
Time frame: perioperatively
Composition of lymphocyte population in mesenteric lymph nodes
Time frame: 3 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Nov 2014.
- Background: PubMed 24268809Leveque L, Hodgson S, Peyton S, Koyama M, MacDonald KP, Khosrotehrani K. Selective organ specific inflammation in offspring harbouring microchimerism from strongly alloreactive mothers. J Autoimmun. 2014 May;50:51-8. doi: 10.1016/j.jaut.2013.10.005. Epub 2013 Nov 20.
- Background: PubMed 17984038Willasch A, Schneider G, Reincke BS, Shayegi N, Kreyenberg H, Kuci S, Weber G, Van Der Reijden B, Niethammer D, Klingebiel T, Bader P. Sequence polymorphism systems for quantitative real-time polymerase chain reaction to characterize hematopoietic chimerism-high informativity and sensitivity as well as excellent reproducibility and precision of measurement. Lab Hematol. 2007;13(3):73-84.
- Derived from this study: PubMed 26756872Engelmann C, Maelzer M, Kreyenberg H. Absence of Maternal Microchimerism in Regional Lymph Nodes of Children With Biliary Atresia. J Pediatr Gastroenterol Nutr. 2016 Jun;62(6):804-7. doi: 10.1097/MPG.0000000000001093.
Related trials for Biliary Atresia
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
Active, not recruitingPhase 3
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia
Biliary Atresia
Active, not recruiting
Molecular Characterization for Understanding Biliary Atresia
Biliary Atresia
Active, not recruitingPhase 3
Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)
Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)
RecruitingPhase 1
Umbilical Cord Mesenchymal Stem Cell Therapy for Biliary Atresia
Biliary Atresia, Kasai Operation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Carsten R Engelmann, MD, OhD principal investigator
Klinikum Brandenburg
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Biliary Atresia, run by Medizinische Hochschule Brandenburg Theodor Fontane at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Nov 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Maternal DNA in offspring (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02292862, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Nov 2014.